IMUX raises €180.0M Growth round
13 February 2026· Mannheim, Germany· manufacturing, energy, robotics, b2b, software_hardware
The proceeds will support Immunic's strategic transition into a commercial entity, including the completion of Phase 3 ENSURE trials in relapsing multiple sclerosis and the initiation of a Phase 3 trial in primary progressive multiple sclerosis.
Investors
LeadBVF Partners L.P.
Also participating
RA Capital ManagementOrbiMedAvidity PartnersVivo CapitalTCGXJanus Henderson InvestorsAberdeen InvestmentsCoastlands CapitalEcoR1 CapitalTrails Edge Capital PartnersWoodline Partners LP
About IMUX
Stage
Growth
Headquarters
Mannheim, Germany
Founded
2020
Team Size
6–20
Sectors
manufacturingenergyroboticsb2bsoftware_hardware